UPDATE: Deutsche Bank Initiates Viropharma at Buy with PT of $37 on Under-Appreciated Pipeline

Deutsche Bank initiated its coverage on Viropharma VPHM with a Buy rating and a price target of $37 a share. Deutsche Bank noted, "We see Viropharma's core drug Cinryze, for HAE, continuing to grow above street & company expectations in the US & EU. We believe competition beyond 2016 when marketing exclusivity expires will slow, but not erode growth. Finally, at these share levels we believe credit is not being assigned to the "other" marketed products Plenadren & Buccolam or the pipeline. Maribavir ph2 , US Plenadren clarity, & VP20621 interim ph2 late '12 as well as EOE ph2 data in 2013 provide upside." Viropharma closed at $27.33 on Tuesday.